- Home
- LAB vs REPL Comparison
LAB vs REPL Comparison
Compare LAB & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- REPL
- Stock Information
- Founded
- LAB 1999
- REPL 2015
- Country
- LAB United States
- REPL United States
- Employees
- LAB N/A
- REPL N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- LAB Industrials
- REPL Health Care
- Exchange
- LAB Nasdaq
- REPL Nasdaq
- Market Cap
- LAB 473.2M
- REPL 547.0M
- IPO Year
- LAB 2011
- REPL 2018
- Fundamental
- Price
- LAB $1.35
- REPL $5.71
- Analyst Decision
- LAB Buy
- REPL Hold
- Analyst Count
- LAB 2
- REPL 9
- Target Price
- LAB $2.50
- REPL $7.00
- AVG Volume (30 Days)
- LAB 1.1M
- REPL 2.1M
- Earning Date
- LAB 10-29-2025
- REPL 11-11-2025
- Dividend Yield
- LAB N/A
- REPL N/A
- EPS Growth
- LAB N/A
- REPL N/A
- EPS
- LAB N/A
- REPL N/A
- Revenue
- LAB $172,271,000.00
- REPL N/A
- Revenue This Year
- LAB N/A
- REPL N/A
- Revenue Next Year
- LAB N/A
- REPL $408.25
- P/E Ratio
- LAB N/A
- REPL N/A
- Revenue Growth
- LAB 76.33
- REPL N/A
- 52 Week Low
- LAB $0.92
- REPL $2.68
- 52 Week High
- LAB $2.32
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- LAB 55.30
- REPL 46.92
- Support Level
- LAB $1.27
- REPL $5.60
- Resistance Level
- LAB $1.41
- REPL $6.15
- Average True Range (ATR)
- LAB 0.08
- REPL 0.33
- MACD
- LAB 0.01
- REPL 0.06
- Stochastic Oscillator
- LAB 68.18
- REPL 32.48
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.